Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated ...

The NanoPortal technology has also been applied in the NPM-115 (exenatide implant) program, with the first human study, LIBERATE-1, progressing as expected. This trial aims to assess the safety ...

Vivani also expects the results to support the potential application of a GLP-1 (exenatide) implant for type 2 diabetes and other diseases. How to Spot the Market Bottom: Matt Maley has navigated ...

Together, these data demonstrate the versatility of the NanoPortal technology beyond NPM-115 (exenatide implant) and provide significant encouragement for continued development of each program.

On Thursday, Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the LIBERATE-1 trial in Australia. Vivani's lead program, NPM-115, ...

On March 13, 2025, Vivani also announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1 clinical trial. This milestone marks a critical step toward addressi ...

Vivani expects these results to support the potential application of this GLP-1 (exenatide) implant in the treatment of type 2 diabetes and other diseases for which GLP-1 treatment has ...